European CHMP recommends license extension of ipilimumab (Yervoy)

The CHMP has recommended approval of ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Source:

European Medicines Agency